Sunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update
“Judy and Par are accomplished leaders who have each made invaluable contributions to our programs, most recently with vecabrutinib. I am pleased to announce these well-deserved promotions, and we look forward to their continued leadership as we prepare for the next stage of our company’s growth,” said
Dr. Fox rejoined Sunesis in 2017 as Chief Scientific Officer and program leader for vecabrutinib, with additional responsibility for much of the R&D organization including translational research and clinical development. She has contributed to the development of a number of promising and marketed therapeutics, and has held roles of increasing responsibility at companies including Genentech, Genencor, and Chiron/
Mr. Hyare joined Sunesis in
The company also announced that it has completed the safety evaluation period for the 200 mg cohort of the ongoing Phase 1b/2 trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. To date, vecabrutinib has a favorable safety profile with no drug-related serious adverse events, supporting dose escalation to Cohort 5 (300 mg). This cohort is now open.
Sunesis is a biopharmaceutical company developing new targeted therapeutics for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies. The company’s proprietary PDK1 inhibitor SNS-510 is in preclinical development. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK, and SGK families. Sunesis is exploring strategic alternatives for vosaroxin, a late-stage investigational product for relapsed or refractory AML. Sunesis also has an interest in the pan-RAF inhibitor TAK-580 which is licensed to Takeda. TAK-580 is in a clinical trial for pediatric low-grade glioma.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
This press release contains forward-looking statements, including statements related to Sunesis’ continued development of vecabrutinib (SNS-062), including the timing and progress of the Phase 1b/2 trial of vecabrutinib, the therapeutic potential of vecabrutinib, and the further development and potential of its kinase inhibitor pipeline. Words such as “believe,” “expect,” “likely,” “look forward” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk related to the timing or conduct of Sunesis' clinical trials, including the vecabrutinib Phase 1b/2 trial, the risk that Sunesis' clinical or preclinical studies for vecabrutinib, SNS-510 or any other product candidate may not demonstrate safety or efficacy or lead to regulatory approval, the risk that data to date and trends may not be predictive of future data or results, that Sunesis' development activities for vecabrutinib or SNS-510 could be otherwise halted or significantly delayed for various reasons, that Sunesis may not be able to receive regulatory approval of vecabrutinib, or SNS-510 in the U.S. or
|Investor and Media Inquiries:|
Sunesis Pharmaceuticals Inc.
Source: Sunesis Pharmaceuticals, Inc.